Monoclonal neutralizing antibodies against SARS-COV-2 S protein

Area of Science:

• Virology
• Immunology
• Drug Discovery

Background:

• Coronavirus disease 2019 (COVID-19) is a severe respiratory illness caused by SARS-CoV-2.
• The SARS-CoV-2 spike (S) protein binds to human ACE2 receptors, facilitating viral entry and infection.
• Effective therapeutic strategies for COVID-19 remain a critical unmet need.

Purpose of the Study:

• To develop high-affinity antibodies targeting the SARS-CoV-2 S protein receptor binding domain (RBD).
• To identify potential therapeutic agents for COVID-19 by neutralizing S protein-ACE2 interactions.

Main Methods:

• Utilized the S protein RBD as a specific antigenic epitope for antibody generation.
• Screened and selected high-affinity antibodies with favorable drug-forming properties.
• Identified monoclonal antibodies 14F4HL and 14E3HL.

Main Results:

• Generated monoclonal antibodies 14F4HL and 14E3HL with high affinity for the SARS-CoV-2 RBD.
• These antibodies demonstrated potent neutralizing capabilities against the S protein.
• The identified antibodies possess suitable properties for further humanization studies.

Conclusions:

• Monoclonal antibodies 14F4HL and 14E3HL are effective neutralizers of the SARS-CoV-2 S protein.
• These antibodies represent promising candidates for the development of novel COVID-19 therapeutics.
• The findings offer new insights into targeted drug development for COVID-19 treatment.